Quarterly ResultAug 7, 2026, 05:11 PM
Immix Biopharma H1 Net Loss $(21.6)M; Cash $232.1M After Offerings
AI Summary
Immix Biopharma, Inc. reported a net loss of $(21.6) million for the six months ended June 30, 2026, an increase from $(11.2) million in the prior year period. Research and development expenses rose to $11.3 million, and general and administrative expenses increased to $11.9 million. The company significantly strengthened its financial position through a $140.7 million underwritten public offering and $13.9 million from an At-The-Market facility during the period. As of June 30, 2026, Immix Biopharma held $232.1 million in cash, cash equivalents, and short-term investments, which is expected to fund operations for at least the next 12 months.
Key Highlights
- Net loss for the six months ended June 30, 2026, was $(21.6) million, compared to $(11.2) million in H1 2025.
- Loss per common share for H1 2026 was $(0.36), compared to $(0.37) in H1 2025.
- Research and development expenses increased to $11.3 million for the six months ended June 30, 2026.
- General and administrative expenses increased to $11.9 million for the six months ended June 30, 2026.
- Cash, cash equivalents, and short-term investments totaled $232.1 million as of June 30, 2026.
- Completed an underwritten public offering in May 2026, raising $140.7 million in net proceeds.
- Raised $13.9 million in net proceeds from At-The-Market facility sales during Q2 2026.
- Received $2.0 million in grant reimbursements from CIRM during the first half of 2026.
Price Impact
More from IMMX